Press Releases Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Search Press Releases Found 265 Results December 7, 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder November 10, 2022 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results November 8, 2022 Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022 October 13, 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder September 20, 2022 Relmada Therapeutics Announces Completion of Treatment in Company’s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder August 11, 2022 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results August 9, 2022 Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder August 5, 2022 Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022 July 21, 2022 Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial June 7, 2022 Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference «...67891011...»
